Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

PURPOSE: The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, Matthew H. G., Varadhachary, Gauri R., Fleming, Jason B., Wolff, Robert A., Lee, Jeffrey E., Pisters, Peter W. T., Vauthey, Jean-Nicolas, Abdalla, Eddie K., Sun, Charlotte C., Wang, Huamin, Crane, Christopher H., Lee, Jeffrey H., Tamm, Eric P., Abbruzzese, James L., Evans, Douglas B.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Gastrointestinal Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889288/
https://www.ncbi.nlm.nih.gov/pubmed/20162463
http://dx.doi.org/10.1245/s10434-010-0943-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889288/
https://www.ncbi.nlm.nih.gov/pubmed/20162463
http://dx.doi.org/10.1245/s10434-010-0943-1

Ejemplares similares